Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
Rheumatology Advances in Practice · 14.09.2024 · 8 (4)
DOI: 10.1093/rap/rkae141 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 07.11.2024. Verfasst von Saad Ahmed und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Medicine, Colchester Hospital, Colchester, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Oxford Biomedical Research Centre.
Abstract (Originalsprache)
Axial spondyloarthritis (axSpA) is a chronic illness with limited treatment options. The role of Janus kinase (JAK) inhibition as a therapeutic option has increasingly become a focus of research in recent years as they have brought a new mode of action to the clinical armamentarium. This review assesses the efficacy and safety profile of these drugs in axSpA. The current phase 2 and 3 clinical trials data are summarized across tofacitinib, upadacitinib and filgotinib. Moreover, the safety profiles of these drugs, in the context of emerging safety signals such as during the ORAL surveillance study, are reviewed. In summary, JAK inhibitors offer a novel therapeutic target for axSpA and appear to address some of the unmet needs for patients who have either failed to respond to current treatment options or in whom they are contraindicated. There is a relative lack of evidence in non-radiographic axSpA and longer-term trials are needed to establish true efficacy and safety profile in radiographic axSpA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Medicine, Colchester Hospital, Colchester, UK.
- School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
- Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK.
ORCID-Profile: Saad Ahmed, Rohan Yesudian, Hassan Ubaide, Laura C Coates
Förderung
- National Institute for Health Research
- Oxford Biomedical Research Centre
Zitieren
APA
Ahmed, S., Yesudian, R., Ubaide, H., & Coates, L. C. (2024). Rationale and concerns for using JAK inhibitors in axial spondyloarthritis. Rheumatology Advances in Practice, 8(4). https://doi.org/10.1093/rap/rkae141
Vancouver
Ahmed S, Yesudian R, Ubaide H, Coates LC. Rationale and concerns for using JAK inhibitors in axial spondyloarthritis. Rheumatology Advances in Practice. 2024;8(4). doi:10.1093/rap/rkae141
BibTeX
@article{Ahmed2024,
author = {Ahmed, Saad and Yesudian, Rohan and Ubaide, Hassan and Coates, Laura C},
title = {Rationale and concerns for using JAK inhibitors in axial spondyloarthritis},
journal = {Rheumatology Advances in Practice},
year = {2024},
volume = {8},
number = {4},
doi = {10.1093/rap/rkae141}
}
EUVIMED